https://pittplusme.org/study/apg777study
APG777 Study
STUDY BASICS
Do you have moderate to severe eczema? You may be eligible for a research study to evaluate the safety and efficacy (how well the drug works) of APG777. Study participation will last approximately 2 years and includes 22 study visits. Compensation is provided.
STUDY PURPOSE
This study is being done to evaluate the safety and efficacy (how well the study drug works) of APG777 in participants with moderate-to-severe atopic dermatitis (AD). Atopic dermatitis (AD), also known as eczema, is a chronic condition that causes dry, itchy, and inflamed skin.
APG777 is an experimental drug, which means it is not yet approved by the Food and Drug Administration (FDA). It is not approved for use outside of studies like this one.
COULD THIS STUDY BE RIGHT FOR YOU?
- 18 years and older
- Be diagnosed by healthcare professional with moderate-to-severe eczema
- Prior topical eczema medications did not work well, or you did not tolerate them
WHAT PARTICIPANTS CAN EXPECT
Study participation will last approximately 2 years and includes 22 study visits. The study will include 52 weeks of treatment followed by approximately 48 to 52 weeks of follow-up period. For the first 16 weeks of treatment, APG777 or placebo will be randomly assigned (like drawing numbers from a hat), and you will have approximately 2 out of 3 chance to get APG777. After week 16 and until week 52 all patients will receive APG777.
IRB: SSU00261151
- APG777-201, A Two-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Apg777 in Patients with Moderate-to-Severe Atopic Dermatitis (Pro00078098)
MEET THE RESEARCHER
Joe K. Tung
Joe K. Tung, MD, MBA received his undergraduate degree in Molecular Biophysics and Biochemistry at Yale University and his medical degree at Harvard Medical School. He concurrently obtained his Master of Business Administration from Harvard Business School, graduating in the top 5% as a Baker Scholar. Dr. Tung went on to complete his internal medicine intern year at the Brigham and Women's Hospital and his dermatology residency at the University of Pittsburgh Medical Center.
Dr. Tung won a gold medal representing the United States at the 43rd International Chemistry Olympiad. His basic science and clinical research work have resulted in multiple peer-reviewed articles, reviews, textbook chapters, clinical decision support tools, and presentations at national and international meetings. He serves as a reviewer for research journals, as a consultant for pharmaceutical and biotechnology companies, as a principal investigator for global industry-sponsored clinical trials, and as an advisor for multiple healthcare start-ups. In his spare time, Dr. Tung enjoys traveling, playing golf, rock climbing, visiting museums, and attending live sporting events.